Skip to content

Chinese Colorectal Cancer Database

Chinese Colorectal Cancer Database

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05434026
Acronym
CCCD
Enrollment
200000
Registered
2022-06-27
Start date
2022-08-03
Completion date
2032-06-22
Last updated
2022-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colonic Cancer, Prospective Studies, Rectal Cancer

Brief summary

1. To establish the Chinese people's own clinical data database of colorectal cancer, reflecting the law and characteristics of colorectal cancer patients in China. 2. Based on colorectal cancer surgery, collect clinical data, especially data on clinical manifestations, complications, laboratory tests, auxiliary examinations, postoperative clinical effects, surgical complications, and colorectal cancer recurrence, so as to lead the direction of clinical practice and academic research of colorectal cancer surgery in China. It provides a certain basis for future research on colorectal cancer. 3. Provide academic consultation and data support to national health authorities.

Interventions

None listed

Sponsors

Beijing Chao Yang Hospital
CollaboratorOTHER
Peking University People's Hospital
CollaboratorOTHER
Peking University Cancer Hospital & Institute
CollaboratorOTHER
Peking Union Medical College Hospital
CollaboratorOTHER
The First Hospital of Jilin University
CollaboratorOTHER
Ruijin Hospital
CollaboratorOTHER
First Hospital of China Medical University
CollaboratorOTHER
Beijing Friendship Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* adenocarcinoma of the colon by biopsy * tolerable to surgery * be able to understand and willing to participate in this trial with signature

Exclusion criteria

* can not tolerate the surgery * history of serious mental illness * the researchers believe the patients should not enrolled in

Design outcomes

Primary

MeasureTime frameDescription
the rate of postoperative complications30 days after surgerypreoperative safety containing operation information, complication information.
Positive rate of circumferential resection margin (CRM) of the specimens10 days after surgeryCircumferential resection margin (CRM) is the distance between the deepest point of tumor in the primary cancer and the margin of resection in the retroperitoneum or mesentery by pathological examination. CRM 0-1mm is defined as positive, while \>1mm is negative.
The grade score of the specimens integrity10 days after surgeryshows the quality of the specimens: grade 1 is bad gross specimen which means incomplete mesorectum and pelvic fascia, and muscle layer can be see \>5mm; grade 3 is high quality gross specimen, which means the specimen is cylindrical, mesorectum and pelvic fascia are complete; grade 2 is between 1and 3.
The distance between lower tumor margin and the lower reaction margin10 days after surgeryshows the oncological safety of the surgery by pathological examination. Reports should contain the distance between lower tumor margin and the lower reaction margin.
local recurrence rate3 years after surgeryshow the oncological efficacy by 3-year follow-up according to the NCCN guideline. Participants should report every follow-up examinations which prove tumor recurrence and/or metastasis or not.
the operative time30 days after surgerypreoperative safety containing operation information, complication information.
postoperative hospital stay3 year after surgeryrecovery information.
the score of postoperative life6 months after surgeryquality of life contains two scales: Wexner scale and EORTC QLQ-CR29 scale, which show quality of life and the anal function.
disease free survival rate3-year after surgeryshow the oncological efficacy by 3-year follow-up according to the NCCN guideline. Participants should report every follow-up examinations which prove tumor recurrence and/or metastasis or not.
overall survival rate3-year after surgeryshow the oncological efficacy by 3-year follow-up according to the NCCN guideline. Participants should report every follow-up examinations which prove tumor recurrence and/or metastasis or not.

Countries

China

Contacts

Primary ContactZhongtao Zhang
zhangzht@ccmu.edu.cn13801060364
Backup ContactHongwei Yao
yaohongwei@ccmu.edu.cn13611015609

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026